MRK vs GILD — Key Metrics
| Metric | MRK (MERCK & CO INC) | GILD (GILEAD SCIENCES INC) |
|---|---|---|
| Price | 137.78 | 168.98 |
| Market Cap | 339.66 Billion | 209.59 Billion |
| P/E (TTM) | 137.78 | -54.51 |
| P/B (Quarterly) | 8.257 | 16.235 |
| P/S (TTM) | 5.04 | 6.76 |
| Net Profit Margin (TTM) | 3.6 | -12.5 |
| Gross Margin (TTM) | 71.8 | 79.9 |
| ROE (TTM) | 5.3 | -21.7 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Outperform
Recommendation Summary
Stock MRK is projected to greatly outperform the market, stock GILD is projected to outperform the market. Upfront Recommendation: MRK.
Financial Metrics
| MRK | Metrics | GILD |
|---|---|---|
| $137.78 | Price | $168.98 |
| — | Market Capitalization | — |
| 5.04 | Price to Sales | 6.76 |
| 23.03 | Price to FCF Ratio | 15.21 |
| 7.03 | Price to Gross Profit | 8.46 |
| 11.04 | Price to R&D | 33.12 |
| 8.72 | Price to Current Assets | 12.66 |
MRK vs GILD at a glance
Merck & CO INC (MRK) and Gilead Sciences INC (GILD) are both Drug Manufacturers - General companies in the Healthcare sector. MRK is the larger, at $339.7 billion in market value against $209.6 billion for GILD, about 1.6 times the size.
On trailing-twelve-month figures, MRK trades at 5.0 times trailing sales and GILD at 6.8; net profit margins are 3.6% and -12.5%.
The Upfront Investment model currently rates MRK Greatly Outperform and GILD Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.